Testosterone replacement therapy (TRT) has not been shown to increase the incidence of prostate cancer when it is used to restore testosterone to physiological levels in appropriately evaluated men with hypogonadism. That does not mean testosterone is irrelevant to prostate cancer. Prostate cells—including many prostate-cancer cells—respond to androgen signaling, which is why lowering testosterone with androgen-deprivation therapy can control established prostate cancer. The important distinction is between causing a new cancer, affecting an existing androgen-sensitive cancer, and restoring low testosterone in a man without known active cancer.
Current European Association of Urology guidance states that testosterone therapy in hypogonadal men does not appear to increase prostate-cancer risk, while also emphasizing that longer prospective follow-up is still needed. In the large randomized TRAVERSE prostate-safety analysis, carefully screened men receiving testosterone had similarly low rates of both high-grade and overall prostate cancer compared with placebo during approximately 33 months of follow-up. However, TRT can increase PSA modestly, men at high prostate-cancer risk were excluded from that trial, and the evidence is much less certain in men with active cancer or a history of prostate cancer.
01Why Is Testosterone Connected to Prostate Cancer Biology?
Normal prostate tissue is androgen-responsive
Testosterone is the principal circulating androgen in men.
Within prostate tissue, some testosterone is converted by 5-alpha-reductase into dihydrotestosterone (DHT), a more potent activator of the androgen receptor.
Androgen signaling helps regulate:
- normal prostate development;
- glandular activity;
- prostate-secretory proteins;
- cell survival;
- and expression of prostate-specific antigen (PSA).
Prostate cancer can also remain androgen-dependent
Most prostate adenocarcinomas initially retain androgen-receptor signaling.
Testosterone or DHT can bind the androgen receptor inside prostate-cancer cells and activate genes involved in cellular growth and survival.
That biological dependence explains why androgen-deprivation therapy (ADT) is effective in many forms of advanced prostate cancer.
Reducing circulating testosterone can sharply reduce androgen-receptor stimulation and suppress cancer activity.
Does that mean more testosterone automatically means more prostate cancer?
No.
The relationship is more complicated than a simple linear equation in which every increase in testosterone produces proportionally greater cancer growth.
Large epidemiological studies have not shown a consistent increase in prostate-cancer incidence among men with naturally higher circulating testosterone concentrations.
Likewise, trials that restore low testosterone into the physiological range have not demonstrated a corresponding increase in prostate-cancer incidence.
What is the androgen-receptor “saturation” concept?
One proposed explanation is that prostate androgen receptors become substantially occupied at relatively low androgen concentrations.
Under this model, moving from very low testosterone toward the physiological range may have a larger effect on androgen-responsive tissue than moving between two already adequate testosterone concentrations.
This concept helps explain why:
- castration-level testosterone strongly suppresses prostate cancer;
- restoring testosterone from severe deficiency can increase PSA modestly;
- yet progressively higher physiological testosterone does not necessarily produce progressively higher prostate-cancer incidence.
However, the saturation concept is a biological model rather than a precise clinical threshold. It should not be used to calculate a “safe testosterone number” for an individual with prostate cancer.
TRT is not the same as supraphysiologic androgen use
Medical testosterone replacement aims to correct confirmed hypogonadism and restore concentrations into a physiological range.
That is different from:
- non-medical anabolic-steroid cycles;
- very high androgen doses;
- unmonitored testosterone use;
- or combining multiple androgenic agents for bodybuilding.
Evidence supporting prostate safety of medically monitored TRT should not automatically be extrapolated to supraphysiologic androgen exposure.
The core distinction: testosterone is biologically relevant to established prostate cancer, but biological relevance does not prove that medically restoring deficient testosterone initiates prostate cancer in men who do not already have known active disease.
02Does Testosterone Replacement Therapy Cause Prostate Cancer?
Current guideline evidence does not show an increased incidence
The 2026 EAU Male Hypogonadism guideline states that available evidence does not support an increased prostate-cancer risk in hypogonadal men receiving testosterone therapy.
EAU’s separate Prostate Cancer guideline reaches the same general conclusion: hypogonadal men receiving testosterone supplementation have not shown an increased incidence of prostate cancer.
What do randomized trials show?
A major limitation of older TRT trials was that most were:
- small;
- short;
- designed primarily to measure sexual or metabolic outcomes;
- and not powered specifically for prostate cancer.
Meta-analyses of placebo-controlled trials nevertheless failed to show a significant increase in prostate-cancer diagnoses among men receiving testosterone.
The evidence became stronger when the large TRAVERSE trial prospectively adjudicated prostate-safety outcomes.
What did TRAVERSE find?
The prostate-safety analysis included 5,204 men aged 45–80 years with:
- symptoms of hypogonadism;
- two testosterone measurements below 300 ng/dL;
- and cardiovascular disease or increased cardiovascular risk.
Participants were randomized to topical testosterone gel or placebo.
Over 14,304 person-years of follow-up:
- 5 of 2,596 testosterone-treated men developed high-grade prostate cancer;
- 3 of 2,602 placebo-treated men developed high-grade prostate cancer;
- 12 testosterone-treated men developed any prostate cancer;
- 11 placebo-treated men developed any prostate cancer;
- and neither comparison was statistically significant.
The trial also found no significant difference in:
- acute urinary retention;
- prostate biopsy;
- new lower-urinary-tract medication use;
- or invasive prostate procedures.
Why does the TRAVERSE result not prove zero lifetime risk?
Prostate cancer can develop over many years.
TRAVERSE had a mean follow-up of roughly 33 months and a mean treatment duration of about 22 months.
That duration is useful for detecting short- and medium-term safety signals but cannot exclude every effect that might emerge after:
- 10 years;
- 20 years;
- or lifelong exposure.
For that reason, the 2026 EAU guideline explicitly states that longer prospective follow-up remains desirable.
What do observational studies show?
Large registries and observational cohorts generally do not show higher prostate-cancer incidence among appropriately treated hypogonadal men.
EAU summarizes registry experience involving thousands of testosterone-treated men with follow-up extending several years without a convincing increase in prostate-cancer incidence.
Observational data are useful for longer follow-up, but they have limitations because treatment is not randomly assigned.
Can TRT raise PSA without causing cancer?
Yes.
PSA production is androgen-responsive.
When a man with low testosterone starts TRT, benign prostate epithelial cells can increase PSA production as androgen signaling normalizes.
TRAVERSE found a significantly greater PSA increase in testosterone-treated men than in the placebo group even though prostate-cancer incidence was similar.
This demonstrates an important clinical distinction:
PSA response and prostate-cancer incidence are not the same outcome.
Could TRT uncover a cancer that was already present?
Potentially.
A microscopic prostate cancer may exist before treatment without having been detected. If PSA subsequently rises, the increased surveillance around TRT can lead to:
- urology referral;
- MRI;
- biopsy;
- and diagnosis of a previously occult cancer.
That timing does not automatically prove that testosterone created the cancer after treatment began.
For appropriately selected men with genuine hypogonadism and no known active prostate cancer, current evidence is reassuring that physiological TRT does not materially increase short- to medium-term prostate-cancer incidence. The strongest uncertainty is long-term exposure and populations that major trials deliberately excluded.
03What If a Man Already Has Prostate Cancer or Was Treated for It?
This is a different clinical question from cancer initiation
A study asking whether TRT causes a new prostate cancer in previously cancer-free men does not automatically answer whether TRT is safe in a man who:
- currently has untreated prostate cancer;
- is on active surveillance;
- has completed prostatectomy;
- has completed radiation;
- has biochemical recurrence;
- or has metastatic disease.
Those populations have different amounts of residual cancer tissue and different dependence on androgen signaling.
Active advanced prostate cancer remains a major contraindication
Testosterone should not be viewed as routine replacement therapy in men with locally advanced or metastatic prostate cancer when androgen suppression is part of cancer control.
EAU Male Hypogonadism guidance lists locally advanced or metastatic prostate cancer among the major contraindications to testosterone therapy.
This reflects the established therapeutic principle that lowering testosterone can suppress androgen-sensitive advanced prostate cancer.
What about men successfully treated with prostatectomy?
This area has become more nuanced.
Retrospective series and small observational studies have not demonstrated a strong recurrence signal in carefully selected men who received TRT after definitive treatment.
However, long-term randomized evidence remains limited.
The 2026 EAU guideline recommends that men considering TRT after prostatectomy be:
- symptomatic and hypogonadal;
- without evidence of active disease;
- at low risk of recurrence;
- at least one year beyond surgery;
- and have PSA below 0.01 ng/mL before treatment under the guideline’s suggested pathway.
EAU rates this recommendation as weak because the supporting evidence remains limited.
What about TRT after radiation therapy?
Available observational evidence has not shown a clear recurrence increase in carefully selected patients after curative radiation.
But the evidence base is less definitive than clinicians would prefer.
Unlike radical prostatectomy, the prostate remains in place after radiation, so PSA does not fall to the same near-zero postoperative state.
PSA interpretation must therefore follow the appropriate post-radiation cancer-surveillance framework.
What about active surveillance?
Evidence is even more limited.
The 2026 EAU guideline advises men on active surveillance that the safety data for testosterone therapy are unclear.
If TRT is considered, the decision requires individualized discussion involving:
- the severity of hypogonadal symptoms;
- Grade Group;
- PSA behavior;
- MRI findings;
- tumor volume;
- life expectancy;
- and the uncertainty of long-term safety data.
What about metastatic prostate cancer?
Standard prostate-cancer management commonly aims to suppress androgen signaling, not restore it.
TRT should therefore not be self-started or continued against an oncology treatment plan in a man receiving androgen deprivation for metastatic or otherwise androgen-sensitive advanced disease.
Is it contradictory that TRT may be considered after treatment while ADT treats cancer?
No.
The situations involve very different cancer burdens.
ADT is used when suppressing androgen signaling is therapeutically important because viable cancer remains or recurrence risk warrants systemic suppression.
TRT after curative treatment is considered only in selected men when clinicians believe:
- there is no current evidence of disease;
- the recurrence risk is acceptably low;
- hypogonadal symptoms are clinically meaningful;
- and intensive PSA surveillance is feasible.
History of prostate cancer requires a different standard of evidence. The absence of increased cancer incidence in men without prostate cancer cannot be used as blanket reassurance for active surveillance, post-radiation disease, recurrent cancer or metastatic cancer. Those situations require disease-specific urological or oncological review.
04How Should PSA and Prostate Cancer Risk Be Assessed Before and During TRT?
TRT should begin with a real diagnosis of hypogonadism
Testosterone should not be prescribed merely because a man feels tired or wants higher testosterone.
Guidelines require a combination of:
- compatible symptoms or signs;
- and repeatedly low morning testosterone concentrations using appropriate testing.
AUA guidance uses a total testosterone concentration below 300 ng/dL as a reasonable diagnostic cutoff when supported by symptoms and confirmed on two separate early-morning measurements.
EAU uses its own biochemical framework and similarly emphasizes symptoms plus confirmed low testosterone.
Why assess the prostate before treatment?
The purpose is not because TRT has been proven to cause prostate cancer.
The purpose is to avoid starting therapy without recognizing an already suspicious prostate-cancer signal.
Baseline evaluation can include:
- age;
- prostate-cancer family history;
- known hereditary variants such as BRCA2;
- previous PSA values;
- current PSA;
- digital rectal examination where appropriate;
- urinary symptoms;
- and previous prostate imaging or biopsy history.
For the broader biomarker pathway, see PSA Testing.
Can TRT cause PSA to rise?
Yes.
A modest increase can occur as prostate tissue responds to restoration of androgen signaling.
A PSA rise after TRT therefore has at least two possible broad interpretations:
- a benign physiological prostate response;
- or an underlying prostate condition that deserves investigation.
TRT does not make it appropriate to assume every PSA rise is benign.
What does the 2026 EAU monitoring framework recommend?
EAU recommends PSA assessment before and during testosterone therapy.
Its monitoring table includes PSA checks at:
- baseline;
- 3 months;
- 12 months;
- and annually thereafter for routine testosterone monitoring, with additional 6-month assessment in prostate-cancer survivors.
Digital rectal examination is included at baseline and then at least annually in the EAU framework when appropriate for prostate-cancer monitoring.
When should a PSA change trigger more investigation?
EAU does not recommend treating one universal PSA change as a prostate-cancer diagnosis.
Instead, a significant rise in:
- total PSA;
- or PSA velocity
should prompt consideration of additional prostate-cancer evaluation in men without a previous cancer diagnosis.
The next steps can include:
- confirming the PSA;
- checking for transient causes;
- reviewing prostate size;
- calculating PSA density;
- prostate MRI;
- and biopsy when the combined risk justifies tissue diagnosis.
What does the Endocrine Society use as a referral trigger?
The Endocrine Society guideline recommends urological consultation during the first 12 months of testosterone therapy when there is:
- a confirmed PSA increase greater than 1.4 ng/mL above baseline;
- a confirmed PSA above 4.0 ng/mL;
- or a new prostate abnormality on digital rectal examination.
These are referral thresholds—not proof of prostate cancer.
Why shouldn’t PSA be interpreted with one universal cutoff?
A PSA concentration reflects more than cancer.
Its meaning depends on:
- age;
- prostate volume;
- baseline PSA;
- family history;
- genetic risk;
- inflammation;
- urinary retention;
- medications;
- and prior testing.
For example, a man with a pathogenic BRCA2 variant has a different baseline cancer probability from a man of the same age without that inherited risk.
What if a man’s PSA is already high before TRT?
An unexplained elevated PSA should be evaluated before starting testosterone therapy rather than ignored.
The appropriate investigation can include:
- repeat PSA;
- urinalysis or infection assessment when clinically relevant;
- prostate examination;
- PSA density;
- MRI;
- and biopsy when indicated.
For the next-step pathway after an abnormal PSA, see What Happens After a High PSA?.
Does TRT require PSA testing in every possible age group?
Prostate-cancer screening should remain clinically appropriate for age and overall health.
EAU specifically notes that PSA and DRE monitoring outside ordinary screening age ranges should be discussed individually because:
- prostate cancer is uncommon in very young men;
- and screening benefit can become limited in older men with substantial competing health risks.
What other monitoring is required during TRT?
TRT monitoring is not limited to the prostate.
Clinicians also assess:
- symptom response;
- serum testosterone;
- hematocrit;
- blood pressure and cardiovascular context;
- fertility goals;
- and treatment-specific adverse effects.
EAU recommends testosterone and hematocrit measurement at 3, 6 and 12 months after therapy begins and annually thereafter, with closer monitoring in patients at higher risk of erythrocytosis.
Why does fertility matter?
Exogenous testosterone suppresses pituitary gonadotropins and can markedly reduce sperm production.
TRT is therefore not the preferred treatment for a man actively trying to father a child.
That issue is separate from prostate-cancer risk but is essential to safe testosterone prescribing.
Do not self-treat a low testosterone number in isolation. Fatigue, erectile problems, low libido and low testosterone can occur for many reasons. Appropriate TRT requires confirmation of hypogonadism, assessment of reversible causes, fertility discussion, hematocrit evaluation and prostate-risk review before long-term treatment.
→Testosterone and Prostate Cancer: What Each Finding Actually Means
| Finding | What it supports | What it does not prove |
|---|---|---|
| Naturally higher testosterone | Large observational studies have not shown a consistent increase in prostate-cancer incidence across physiological concentrations. | That androgen signaling is irrelevant to established prostate cancer. |
| Low testosterone + TRT | Current trials do not show increased short- to medium-term prostate-cancer incidence when TRT restores physiological levels in appropriately screened men. | Zero lifetime risk after decades of treatment. |
| PSA rises after TRT | Benign prostate tissue can respond to restored androgen signaling. | That the PSA increase is automatically harmless. |
| Stable PSA during TRT | Reassuring longitudinal prostate signal. | That prostate cancer is impossible. |
| Large or persistent PSA increase | Further prostate evaluation may be needed. | That TRT created prostate cancer. |
| Active advanced prostate cancer | Androgen suppression may be a therapeutic goal. | That evidence from cancer-free TRT trials applies to this population. |
| After radical prostatectomy with no recurrence | Selected low-recurrence-risk men may be considered for TRT under careful surveillance in EAU guidance. | That long-term safety has been proven for every survivor. |
| Active surveillance | Small observational datasets exist. | That safety is established; current EAU guidance describes the evidence as unclear. |
| After radiotherapy | Observational series are somewhat reassuring. | That recurrence risk is definitively unchanged. |
| Supraphysiologic anabolic-steroid use | A biologically different exposure from guideline-based TRT. | That medical TRT safety data can be automatically extrapolated to high-dose non-medical androgen use. |
?Common Questions About TRT and Prostate Cancer
| Question | Practical answer |
|---|---|
| Does testosterone cause prostate cancer? | Current evidence does not show that physiological testosterone concentrations or medically indicated TRT cause prostate cancer in appropriately evaluated hypogonadal men. |
| Does TRT increase prostate cancer risk? | Randomized and pooled evidence has not demonstrated a significant increase, although very long-term data remain limited. |
| What does the 2026 EAU guideline say? | It states that testosterone therapy does not appear to increase prostate-cancer risk, while noting that longer prospective follow-up remains necessary. |
| What did TRAVERSE find? | High-grade and overall prostate-cancer incidence were low and not significantly different between testosterone and placebo groups in carefully screened hypogonadal men. |
| How many men were in the TRAVERSE prostate analysis? | 5,204 men contributed 14,304 person-years of follow-up. |
| Did TRT raise PSA in TRAVERSE? | Yes. PSA increased more in the testosterone group even though prostate-cancer incidence did not differ significantly. |
| Does a PSA increase after TRT mean cancer? | No. Benign prostate tissue is androgen-responsive, but an unexpected PSA rise still requires appropriate evaluation. |
| Can TRT uncover an existing prostate cancer? | Increased PSA surveillance can lead to detection of a cancer that may already have been present before treatment. |
| Does TRT make the prostate bigger? | Androgen restoration can affect benign prostate tissue, but clinically important changes vary among men and are not equivalent to prostate cancer. |
| Does high natural testosterone mean higher prostate cancer risk? | Large observational data have not demonstrated a consistent simple linear association across normal testosterone concentrations. |
| Why does ADT work if testosterone does not cause cancer? | Many established prostate cancers depend on androgen-receptor signaling. Removing that growth signal can suppress existing cancer without implying that physiological testosterone initiated the original cancer. |
| What is the testosterone saturation model? | It is a proposed biological model in which androgen-receptor response rises strongly at low concentrations and becomes less responsive once receptor signaling is substantially occupied. It is not a precise individual safety threshold. |
| Can someone with active prostate cancer take TRT? | Routine TRT is not appropriate in advanced androgen-sensitive prostate cancer, and active cancer requires specialist disease-specific assessment. |
| Can someone take TRT after prostatectomy? | Selected symptomatic men with low recurrence risk and no evidence of disease may be considered after careful counseling and surveillance. |
| How long after prostatectomy does EAU suggest waiting? | The 2026 EAU guideline suggests at least one year in selected low-recurrence-risk men, with PSA below 0.01 ng/mL and no evidence of recurrence. |
| Can someone on active surveillance use TRT? | Evidence remains limited and current EAU guidance describes safety in this group as unclear. |
| Can someone use TRT after radiation? | It may be considered in selected circumstances, but long-term evidence remains limited and PSA must be interpreted using post-radiation cancer-surveillance principles. |
| Does TRT increase metastatic prostate cancer? | Current cancer-free TRT trials have not demonstrated an increased metastatic cancer signal, but they were not designed to answer every decades-long risk question. |
| Should PSA be checked before TRT? | Yes when age and clinical context make prostate monitoring appropriate, together with prostate-risk assessment. |
| How often does EAU monitor PSA during TRT? | Its monitoring framework includes baseline, 3 months, 12 months and annual PSA assessment, with additional monitoring for prostate-cancer survivors. |
| What PSA change triggers Endocrine Society referral? | During the first year, a confirmed rise greater than 1.4 ng/mL above baseline, confirmed PSA above 4.0 ng/mL or new abnormal DRE prompts urological consultation. |
| Does that PSA threshold diagnose cancer? | No. It indicates the need for urological evaluation. |
| What if PSA is high before TRT? | The prostate abnormality should be evaluated before treatment rather than attributing it to low testosterone. |
| Does BRCA2 matter before TRT? | Yes. BRCA2 increases baseline prostate-cancer susceptibility and therefore changes the pre-treatment prostate-risk context. |
| Is TRT the same as anabolic steroid use? | No. Medical TRT aims for physiological replacement; high-dose anabolic-androgen use creates a different exposure that is not covered by standard TRT safety evidence. |
| Can TRT reduce fertility? | Yes. Exogenous testosterone suppresses gonadotropins and sperm production and should not be treated as fertility-preserving therapy. |
ΣKey Clinical Takeaways
| Principle | Evidence-based interpretation |
|---|---|
| Testosterone is biologically relevant to the prostate | Normal and malignant prostate cells can respond to androgen-receptor signaling. |
| Biological relevance ≠ cancer causation | Physiological TRT has not been shown to initiate prostate cancer at a higher rate in appropriately selected hypogonadal men. |
| TRAVERSE is reassuring | High-grade and overall prostate cancers were similarly uncommon with testosterone and placebo during roughly 33 months of follow-up. |
| TRAVERSE has boundaries | Men with higher baseline prostate-cancer risk and PSA above 3 ng/mL were excluded. |
| Long-term data remain incomplete | Trials lasting a few years cannot exclude every decades-long risk. |
| PSA can rise | Restored androgen signaling can increase PSA without necessarily indicating cancer. |
| Unexpected PSA still matters | A large or persistent PSA change deserves confirmation and risk-directed investigation. |
| Active cancer is different | Evidence from cancer-free hypogonadal men should not be generalized to active advanced prostate cancer. |
| Post-treatment TRT may be possible | Selected men with no evidence of active disease may be considered after counseling and specialist surveillance. |
| Genetic risk still applies | BRCA2, family history, age and ancestry remain relevant when evaluating prostate risk before TRT. |
| TRT requires a diagnosis | Symptoms plus repeatedly low testosterone are required; testosterone should not be prescribed solely to raise a laboratory number. |
| Fertility is a separate safety issue | Exogenous testosterone can markedly suppress sperm production. |
Clinical bottom line: current evidence does not support the idea that properly prescribed testosterone replacement causes prostate cancer in appropriately evaluated men with genuine hypogonadism. Testosterone remains biologically important to prostate tissue, PSA can increase after treatment, and existing prostate cancer requires a very different risk discussion. The safest interpretation is therefore neither “testosterone feeds every prostate cancer” nor “TRT has zero prostate relevance,” but rather: confirm hypogonadism, assess baseline prostate risk, replace to physiological levels when appropriate, monitor PSA, and use specialist review when cancer is known or suspected.
Medical disclaimer: This article provides general medical education about testosterone replacement therapy and prostate cancer. It does not determine whether an individual should start, stop or continue testosterone. TRT requires confirmation of hypogonadism and assessment of prostate risk, fertility goals, hematocrit and other medical factors. Men with known prostate cancer, unexplained PSA abnormalities or substantial inherited cancer risk should discuss treatment with qualified urology, endocrinology or oncology clinicians.
For the overall disease pathway from risk through PSA, MRI, biopsy, grading, staging and treatment, return to the Prostate Cancer hub. For other proposed prostate-cancer associations, see Prostate Cancer Risk Factors. For the previous evidence review, see Vasectomy and Prostate Cancer Risk. For inherited high-risk context, see BRCA1, BRCA2 and Prostate Cancer. For PSA interpretation before or during testosterone therapy, see PSA Testing. The next guide explains how prostate cancer is diagnosed, including PSA, digital rectal examination, MRI and biopsy.
Evidence Sources
- European Association of Urology — Prostate Cancer Epidemiology and Aetiology: testosterone supplementation and prostate-cancer incidence.
- European Association of Urology — Male Hypogonadism Guideline (2026): prostate-cancer evidence, contraindications and PSA monitoring during testosterone therapy.
- European Association of Urology — 2026 Sexual and Reproductive Health Guideline Update: revised prostate-cancer and testosterone-therapy recommendations.
- Bhasin S, et al. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: Randomized Clinical Trial. JAMA Network Open. 2023.
- Endocrine Society — Testosterone Therapy for Hypogonadism: prostate-risk assessment, contraindications and PSA referral criteria.
- American Urological Association — Evaluation and Management of Testosterone Deficiency: evidence concerning testosterone therapy and prostate-cancer development.
